AB Soft The Brief Pain Inventory ii - Manual (Page 12)

19
metastases in cancer patients]. Nippon Igaku Hoshasen
Gakkai Zasshi 65(4): 399-410, 10/2005.
24. Pistevou-Gompaki K, Kouloulias VE, Varveris C, Mystakidou K,
Georgakopoulos G, Eleftheriadis N, Gompakis N, Kouvaris J.
Radiotherapy plus either transdermal fentanyl or paracetamol
and codeine for painful bone metastases: a randomised
study of pain relief and quality of life. Curr Med Res Opin
20(2): 159-163, 2004.
25. Saad F. Clinical benefit of zoledronic acid for the prevention
of skeletal complications in advanced prostate cancer. Clin
Prostate Cancer 4(1): 31-37, 6/2005.
26. Tester W, Ackler J, Tijani L, Leighton J. Phase I/II study of weekly
docetaxel and vinblastine in the treatment of metastatic
hormone-refractory prostate carcinoma. Cancer J 12(4): 299-
304, 7/2006.
27. Thanos L, Mylona S, Galani P, Tzavoulis D, Kalioras V, Tanteles
S, Pomoni M. Radiofrequency ablation of osseous metastases
for the palliation of pain. Skeletal Radiol 37(3): 189-194,
3/2008.
28. Vassiliou V, Kalogeropoulou C, Christopoulos C, Solomou E,
Leotsinides M, Kardamakis D. Combination ibandronate and
radiotherapy for the treatment of bone metastases: Clinical
evaluation and radiologic assessment. Int J Radiat Oncol Biol
Phys 67(1): 264-272, 1/2007.
29. Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J,
Dodwell D, Murphy R, Mason T, Cameron D. Zoledronic acid
significantly improves pain scores and quality of life in breast
cancer patients with bone metastases: a randomised,
crossover study of community vs hospital bisphosphonate
administration. Br J Cancer 92(10): 1869-1876, 5/2005.
30. Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F.
Effect of zoledronic acid on pain associated with bone
metastasis in patients with prostate cancer. Ann Oncol 17(6):
986-989, 6/2006.
31. Wu JS, Monk G, Clark T, Robinson J, Eigl BJ, Hagen N. Palliative
radiotherapy improves pain and reduces functional
20
interference in patients with painful bone metastases: a
quality assurance study. Clin Oncol (R Coll Radiol ) 18(7): 539-
544, 9/2006.
32. Yamada K, Kohno N. [Efficacy of bisphosphonates for bone
pain control]. Nippon Rinsho 65(1): 152-156, 1/2007.
Cancer Epidemiology
1. Beck SL, Falkson G. Prevalence and management of cancer
pain in South Africa. Pain 94(1): 75-84, 10/2001.
2. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH,
Stewart JA, Pandya KJ. Pain and its treatment in outpatients
with metastatic cancer. N Engl J Med 330(9): 592-596, 3/1994.
3. Cleeland CS, Gonin R, Baez L, Loehrer P, Pandya KJ. Pain and
treatment of pain in minority patients with cancer. The Eastern
Cooperative Oncology Group Minority Outpatient Pain Study.
Ann Intern Med 127(9): 813-816, 11/1997.
4. Costantini M, Viterbori P, Flego G. Prevalence of pain in Italian
hospitals: results of a regional cross-sectional survey. J Pain
Symptom Manage 23(3): 221-230, 3/2002.
5. Crosby FE, Colestro J, Ventura MR, Graham K. Survey of pain
among veterans in western New York. Pain Manag Nurs 7(1):
12-22, 3/2006.
6. Enting RH, Oldenmenger WH, Van Gool AR, van der Rijt CC,
Sillevis Smitt PA. The effects of analgesic prescription and
patient adherence on pain in a Dutch outpatient cancer
population. J Pain Symptom Manage 34(5): 523-531, 11/2007.
7. Everdingen MHJV, de Rijke JM, Kessels AG, Schouten HC, van
Kleef M, Patijn J. High prevalence of pain in patients with
cancer in a large population-based study in The Netherlands.
Pain 132(3): 312-320, 12/2007.
8. Garbez RO, Chan GK, Neighbor M, Puntillo K. Pain after
discharge: a pilot study of factors associated with pain
management and functional status. Journal of Emergency
Nursing 32(4): 288-293, 8/2006.